Lipid apheresis after heart transplantation - The dresden experience;Lipidapherese nach herztransplantation - Erfahrungen aus dresden

Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

Volumn 22, Issue 4, 2010, Pages 355-362

  Julius, U ^a   Tselmin, S ^a   Fischer, S ^a   Passauer, J ^a   Tsourdi, E ^a   Bornstein, S R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cardiac allograft vasculopathy; Dyslipidemia; Fibrinogen; Heart transplantation; Lipid apheresis; Survival

Indexed keywords

EID: 78650209325     PISSN: 09469648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Schmauss D, Weis M (2008) Cardiac allograft vasculopathy: recent developments. Circulation 117: 2131-41
2. Wang SS (2008) Treatment and prophylaxis of cardiac allograft vasculopathy. Transplant Proc 40: 2609-10
3. Sanchez Lazaro IJ, Almenar Bonet L, Moro Lopez J,, et al. (2008) Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation. Transplant Proc 40: 3056-7
4. Velez M, Johnson MR (2009) Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando) 23: 235-47
5. Raichlin E, Edwards BS, Kremers WK, et al. (2009) Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant 28: 320-7
6. Pflugfelder PW, Boughner DR, Rudas L, Kostuk WJ (1993) Enhanced detection of cardiac allograft arterial disease with intracoronary ultrasonographic imaging. Am Heart J 125: 1583-91
7. St Goar FG, Pinto FJ, Alderman EL, et al. (1992) Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. Circulation 85: 979-87
8. Bocksch W, Wellnhofer E, Klimek W, et al. (2002) Intravascular ultrasound assessment of longitudinal plaque distribution patterns in patients with angiographically silent coronary artery disease after heart transplantation. Coron Artery Dis 13: 349-56
9. Spes CH, Klauss V, Rieber J, et al. (1999) Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound. J Heart Lung Transplant 18: 391-8
10. Jeremias A, Kolz ML, Ikonen TS, et al. (1999) Feasibility of in vivo intravascular ultrasound tissue characterization in the detection of early vascular transplant rejection. Circulation 100: 2127-30
11. Konig A, Kilian E, Sohn HY, et al. (2008) Assessment and characterization of time-related differences in plaque composition by intravascular ultrasound-derived radiofrequency analysis in heart transplant recipients. J Heart Lung Transplant 27: 302-9
12. Raichlin E, Bae JH, Kushwaha SS, et al. (2009) Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 53: 1279-86
13. Knollmann FD, Stuhmer F, Lehmkuhl H, Felix R, Hetzer R (2009) Progression of coronary atherosclerosis after heart transplantation on electronbeam computed tomography. Acad Radiol 16: 194-9
14. Mondillo S, Maccherini M, Galderisi M (2008) Usefulness and limitations of transthoracic echocardiography in heart transplantation recipients. Cardiovasc Ultrasound 6: 2
15. Nguyen T, Ahmadie R, Fang T, et al. (2008) Stress Echocardiography: Abnormal Tissue Doppler Imaging in the Absence of Cardiac Allograft Vasculopathy in Heart Transplant Recipients. Echocardiography
16. Mastrobuoni S, Bastarrika G, Ubilla M, et al. (2009) Dual-source CT coronary angiogram in heart transplant recipients in comparison with dobutamine stress echocardiography for detection of cardiac allograft vasculopathy. Transplantation 87: 587-90
17. Osto E, Tona F, Angelini A, et al. (2009) Determinants of coronary flow reserve in heart transplantation: a study performed with contrast-enhanced echocardiography. J Heart Lung Transplant 28: 453-60
18. Usta E, Burgstahler C, Aebert H, et al. (2009) The challenge to detect heart transplant rejection and transplant vasculopathy non-invasively-a pilot study. J Cardiothorac Surg 4: 43
19. Korosoglou G, Osman NF, Dengler TJ, et al. (2009) Strain-encoded cardiac magnetic resonance for the evaluation of chronic allograft vasculopathy in transplant recipients. Am J Transplant 9: 2587-96
20. Schepis T, Achenbach S, Weyand M, et al. (2009) Comparison of dual source computed tomography versus intravascular ultrasound for evaluation of coronary arteries at least one year after cardiac transplantation. Am J Cardiol 104: 1351-6
21. Konig A, Kilian E, Rieber J, et al. (2008) Assessment of early atherosclerosis in de novo heart transplant recipients: analysis with intravascular ultrasound-derived radiofrequency analysis. J Heart Lung Transplant 27: 26-30
22. Soleimani B, Fu F, Lake P, Shi VC (2008) Development of a combined heart and carotid artery transplant model to investigate the impact of acute rejection on cardiac allograft vasculopathy. J Heart Lung Transplant 27: 450-6
23. Belperio JA, Ardehali A (2008) Chemokines and transplant vasculopathy. Circ Res 103: 454-66
24. Bayliss J, Bailey M, Leet A, Stein AN, Thomson NM, McLean CA (2008) Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy. Transplantation 86: 991-7
25. Thomas HE, Parry G, Dark JH, Arthur HM, Keavney BD (2009) Circulating endothelial progenitor cell numbers are not associated with donor organ age or allograft vasculopathy in cardiac transplant recipients. Atherosclerosis 202: 612-6
26. Mehra MR, Ventura HO, Stapleton DD, Karsan AK, Smart FW, Ramee SR, Collins TJ (1997) Allograft aortopathy: an in vivo study of donor aorta involvement in cardiac allograft vasculopathy. Am Heart J 133: 698-702
27. Bozbas H, Altin C, Yildirir A, et al. (2008) Lipid profiles of patients with a transplanted heart before and after the operation. Transplant Proc 40: 263-6
28. Raichlin E, McConnell JP, Bae JH, Kremers WK, Lerman A, Frantz RP (2008) Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation 85: 963-8
29. Raichlin ER, McConnell JP, Lerman A, et al. (2007) Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant 26: 826-33
30. Valantine H, Rickenbacker P, Kemna M, et al. (2001) Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 103: 2144-52
31. Kato T, Chan MC, Gao SZ, et al. (2004) Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 43: 1034-41
32. Sipahi I, Starling RC (2007) Cardiac allograft vasculopathy: an update. Heart Fail Clin 3: 87-95
33. Hunt SA, Haddad F (2008) The changing face of heart transplantation. J Am Coll Cardiol 52: 587-98
34. Hedman M, Pahlman R, Sundvall J, et al. (2007) Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy. Pediatr Transplant 11: 481-90
35. Ballantyne CM, el Masri B, Morrisett JD, Torre-Amione G (1997) Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol 12: 153-60
36. Hernandez JM, de Prada JA, Burgos V, et al. (2009) Virtual histology intravascular ultrasound assessment of cardiac allograft vasculopathy from 1 to 20 years after heart transplantation. J Heart Lung Transplant 28: 156-62
37. Martinez-Dolz L, Almenar L, Reganon E, et al. (2008) Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant 27: 760-6
38. Wenke K, Thiery J, Arndtz N, Meiser BM, Seidel D, Reichart B (1992) Treatment of hypercholesterolemia and prevention of coronary artery disease after heart transplantation by combination of low-dose simvastatin and HELP-LDL-apheresis. Transplant Proc 24: 2674-6
39. Thiery J, Meiser B, Wenke K, Engelschalk C, Reichart B, Seidel D (1995) Heparin-induced extracorporeal low-density-lipoprotein plasmapheresis (HELP) and its use in heart transplant patients with severe hypercholesterolemia. Transplant Proc 27: 1950-3
40. Jaeger BR, Schirmer J, Thiery J, et al. (1999) Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients. Ther Apher 3: 214-8
41. Jaeger BR, Meiser B, Nagel D, et al. (1997) Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 96: II-154-8
42. Park JW, Merz M, Braun P (1997) Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 16: 290-7
43. Valantine H, Pinto FJ, St Goar FG, Alderman EL, Popp RL (1992) Intracoronary ultrasound imaging in heart transplant recipients: the Stanford experience. J Heart Lung Transplant 11: S60-4
44. Kofler S, Bigdeli AK, Kaczmarek I, et al. (2009) Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center. Transpl Int 22: 1140-50
45. Iyer A, Brown L (2009) Is mycophenolate more than just an immunosuppressant? An overview. Indian J Biochem Biophys 46: 25-30
46. Dandel M, Jasaityte R, Lehmkuhl H, Knosalla C, Hetzer R (2009) Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Transplant Proc 41: 2585-8
47. Wenke K, Meiser B, Thiery J, et al. (1997) Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96: 1398-402
48. Paraskevas KI (2008) Applications of statins in cardiothoracic surgery: more than just lipid-lowering. Eur J Cardiothorac Surg 33: 377-90
49. Kobashigawa JA, Katznelson S, Laks H, et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-7
50. Sadoni S, Kaczmarek I, Delgado O, Schmockel M, Reichart B, Meiser B (2007) Fluvastatin as comedication in heart transplant recipients with elevated creatine-kinase. Transplant Proc 39: 558-9
51. Yin R, Zhu J, Shao H, et al. (2007) Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy. J Heart Lung Transplant 26: 485-93
52. Aliabadi AZ, Mahr S, Dunkler D, et al. (2008) Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 86: 1771-6
53. See Jr. VY, DeNofrio D, Goldberg L, et al. (2003) Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol 92: 11-5
54. Shirakawa I, Sata M, Saiura A, et al. (2007) Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Biomed Pharmacother 61: 154-9
55. Skalicka B, Kubanek M, Malek I, et al. (2009) Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin. J Heart Lung Transplant 28: 598-604
56. Patel AR, Ambrose MS, Duffy GA, Cote H, De-Nofrio D (2007) Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. J Heart Lung Transplant 26: 281-4
57. Moro J, Almenar L, Martinez-Dolz L, et al. (2007) Ezetimibe in heart transplantation: initial experience. Transplant Proc 39: 2389-92
58. Quarta CC, Potena L, Grigioni F, et al. (2008) Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J Heart Lung Transplant 27: 685-8
59. Crespo-Leiro MG, Paniagua MJ, Marzoa R, et al. (2008) The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Transplant Proc 40: 3060-2
60. Shaw SM, Chaggar P, Ritchie J, et al. (2009) The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation 87: 771-5
61. Le VV, Racine N, Pelletier GB, Carrier M, Cossette M, White M (2009) Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy. Clin Transplant 23: 249-55
62. Shaw SM, Najam O, Khan U, Yonan N, Williams SG, Fildes JE (2009) Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients invitro. Transpl Immunol 21: 179-82
63. Fildes JE, Shaw SM, Mitsidou A, et al. (2008) HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. Transpl Immunol 19: 152-7
64. Hasegawa T, Iwanaga K, Hultquist DE, Liao H, Visovatti SH, Pinsky DJ (2009) Suppression of nitrosative and oxidative stress to reduce cardiac allograft vasculopathy. Am J Physiol Heart Circ Physiol 296: H1007-16
65. Yin R, Huang H, Zhang J, Zhu J, Jing H, Li Z (2008) Dietary n-3 fatty acids attenuate cardiac allograft vasculopathy via activating peroxisome proliferator-activated receptor-gamma. Pediatr Transplant 12: 550-6
66. Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D (2006) Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 10: 510-7
67. Jaeger BR, Bengel FM, Odaka K, et al. (2005) Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography. J Heart Lung Transplant 24: 2022-30
68. Cattin L, Petrucco A, Cazzolato G, et al. (1997) Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells. ASAIO J 43: 209-13
69. Julius U, Siegert G, Gromeier S (2000) Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Artif Organs 23: 199-206
70. Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R (2002) Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 25: 1180-8
71. Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, Seidel D (2004) Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 175: 145-50
72. Spieker LE, Ruschitzka F, Badimon JJ, Noll G, Corti R (2004) Shear stress-dependent platelet function after LDL cholesterol apheresis. Thromb Res 113: 395-8
73. Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T (2006) LDL-apheresis reduces P-Selectin, CRP and fibrinogen-possible important implications for improving atherosclerosis. Ther Apher Dial 10: 219-23
74. Moriarty PM, Gibson CA, Shih J, Matias MS (2001) C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158: 495-8
75. Kobayashi J, Katsube S, Shimoda M, et al. (2002) Single LDL apheresis improves serum remnantlike particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin Chim Acta 321: 107-12
76. Otto C, Geiss HC, Empen K, Parhofer KG (2004) Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis 174: 151-6
77. Sakurai M, Muso E, Matushima H, Ono T, Sasayama S (1999) Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int Suppl 71: S210-2
78. Opole IO, Belmont JM, Kumar A, Moriarty PM (2007) Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am J Cardiol 100: 1416-8
79. Empen K, Otto C, Brodl UC, Parhofer KG (2002) The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apher 17: 38-43
80. Mellwig KP (2003) Heparin-induced extracorporeal low-density lipoprotein precipitation. Ther Apher Dial 7: 365-9
81. Dihazi H, Koziolek MJ, Sollner T, et al. (2008) Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transplant 23: 2925-35
82. Blessing F, Jaeger BR, Oberhoffer M, Reichart B, Seidel D (2003) Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses). Z Kardiol 92: III42-7
83. Zakliczynski M, Swierad M, Zakliczynska H, Maruszewski M, Buszman P, Zembala M (2005) Usefulness of stanford scale of intimal hyperplasia assessed by intravascular ultrasound to predict time of onset and severity of cardiac allograft vasculopathy. Transplant Proc 37: 1343-5
84. Tjang YS, van der Heijden GJ, Tenderich G, Grobbee DE, Korfer R (2008) Survival analysis in heart transplantation: results from an analysis of 1290 cases in a single center. Eur J Cardiothorac Surg 33: 856-61
85. Roussel JC, Baron O, Perigaud C, et al. (2008) Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality. J Heart Lung Transplant 27: 486-93
86. Deuse T, Haddad F, Pham M, et al. (2008) Twentyyear survivors of heart transplantation at Stanford University. Am J Transplant 8: 1769-74
87. Gupta A, Mancini D, Kirtane AJ, et al. (2009) Value of drug-eluting stents in cardiac transplant recipients. Am J Cardiol 103: 659-62
88. Bhama JK, Nguyen DQ, Scolieri S, et al. (2009) Surgical revascularization for cardiac allograft vasculopathy: Is it still an option? J Thorac Cardiovasc Surg 137: 1488-92